# LUNAC Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/lunac-therapeutics

- Industry: Pharmaceuticals
- Headquarters: Leeds, UK
- Website: www.lunactherapeutics.com
- Total disclosed funding: $3.3M
- Latest round: Series A (Sep 20, 2019)
- Investors on record: 2

## About

LUNAC Therapeutics Limited is focused on developing innovative anticoagulant therapies, creating first-in-class medications aimed at preventing life-threatening thrombotic events with enhanced safety profiles.LUNAC Therapeutics Limited, founded in 2018 in Leeds, UK, specializes in the development of next-generation anticoagulants. The company has successfully completed 3 deals, with its most recent funding round occurring on May 13, 2021, during which it raised GBP 4.75 million from investors including British Business Bank, Caribou Property Limited, Epidarex Capital, and Mercia Asset Management. The company is led by CEO Julian Howell.LUNAC Therapeutics specializes in the development of next-generation anticoagulant therapies, specifically focusing on first-in-class oral and intravenous medications designed to treat and prevent life-threatening thrombotic events. Their primary innovation is centered around the inhibition of activated Factor XII (FXIIa), addressing a significant clinical need for safer anticoagulation options in healthcare settings, particularly among patients at risk of thromboembolic disorders across North America, Europe, and Asia.LUNAC Therapeutics operates within a business model focusing on B2B transactions with hospitals, healthcare providers, and pharmacies for the distribution of their anticoagulant products. Revenue is generated through partnerships with healthcare institutions and potential licensing agreements for the commercialization of their therapies. Their flagship products are aligned with innovative therapeutic benefits, with revenue streams anticipated to include direct sales, contractual agreements for clinical usage, and collaborative partnerships for broader market access.In May 2021, LUNAC Therapeutics Limited raised GBP 4.75 million in venture funding, which will be utilized to prepare for clinical studies and advance pre-clinical and manufacturing development programs. The company is also planning to launch new products that enhance their current offerings and expand into new geographic markets, specifically targeting North America, Europe, and Asia by 2023.

## Funding rounds

- Series A, Sep 20, 2019, $3.3M — Epidarex Capital, University of Leeds

## Investors

- Epidarex Capital (https://capitalatlas.ai/funds/epidarex-capital) — Series A
- University of Leeds — Series A